Literature DB >> 9751010

Incidence and clinical significance of hepatitis B virus precore gene translation initiation mutations in e antigen-negative patients.

A Laras1, J Koskinas, K Avgidis, S J Hadziyannis.   

Abstract

Hepatitis Be antigen (HBeAg)-negative chronic hepatitis B (CHB) is associated with hepatitis B virus (HBV) variants harbouring changes in the precore region. Most commonly, a G to A point mutation at nucleotide 1896 (m1896) creates a novel translation stop codon that prevents HBeAg production. In the Mediterranean region the m1896 mutation prevails in greater than 98% of HBeAg-negative CHB patients. In this study the prevalence of additional mutations in the precore region was investigated among patients with chronic HBV infection. Precore sequences were determined by sequencing serum HBV DNA amplified by polymerase chain reaction (PCR) with primers flanking the precore/core region. Thirty-one HBeAg-negative and five HBeAg-positive individuals were studied. All HBeAg-negative patients (100%) harboured the m1896 mutation and 20 (64.5%) also had a G to A mutation at nucleotide 1899 (m1899). Additional mutations affecting the translation initiation of the precore gene were found in seven (22.5%) patients, all with active liver disease, five of whom had episodes of HBV reactivation. HBeAg-positive patients had no mutations in these positions and neither did any of the five BHeAg-negative patients with normal levels of liver enzymes, representing the healthy carrier state of HBV infection. Serial sample analysis from one patient revealed that the initiation codon mutation developed following HBeAg seroconversion and the appearance of m1896. During periods of high HBV replication, the ratio of mutant to wild-type ATG was found to increase in parallel with HBV DNA levels. These data show that a significant proportion of HBeAg-negative patients who already harbour the 1896 stop codon mutation may subsequently develop precore translation initiation mutations, which appear to be associated with enhanced HBV replication and severe liver disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9751010     DOI: 10.1046/j.1365-2893.1998.00109.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  22 in total

1.  Expression of RNase H of human hepatitis B virus polymerase in Escherichia coli.

Authors:  Hong Cheng; Hui-Zhong Zhang; Wan-An Shen; Yan-Fang Liu; Fu-Cheng Ma
Journal:  World J Gastroenterol       Date:  2003-03       Impact factor: 5.742

2.  Hepatitis B virus kinetics under antiviral therapy sheds light on differences in hepatitis B e antigen positive and negative infections.

Authors:  Ruy M Ribeiro; Georgios Germanidis; Kimberly A Powers; Bertrand Pellegrin; Paul Nikolaidis; Alan S Perelson; Jean-Michel Pawlotsky
Journal:  J Infect Dis       Date:  2010-11-01       Impact factor: 5.226

3.  Full-length genome characterization of hepatitis B virus genotype H strain isolated from serum samples collected from two chronically infected patients in Argentina.

Authors:  Diego Flichman; Omar Galdame; Beatriz Livellara; Marcela Viaut; Adrian Gadano; Rodolfo Campos
Journal:  J Clin Microbiol       Date:  2009-09-30       Impact factor: 5.948

4.  Relationship between serum b2-microglobulin levels and virological breakthrough in HBeAg-negative chronic hepatitis B patients, under long-term treatment schedules including lamivudine.

Authors:  Ioannis-S Elefsiniotis; Antonios Moulakakis; Konstantinos-D Pantazis; Irene Glynou; Ioannis Ketikoglou; Elena Vezali; Helen Kada; Epameinondas Tsianos
Journal:  World J Gastroenterol       Date:  2005-04-07       Impact factor: 5.742

Review 5.  Lamivudine. A review of its therapeutic potential in chronic hepatitis B.

Authors:  B Jarvis; D Faulds
Journal:  Drugs       Date:  1999-07       Impact factor: 9.546

Review 6.  Risk and management of blood-borne infections in health care workers.

Authors:  E M Beltrami; I T Williams; C N Shapiro; M E Chamberland
Journal:  Clin Microbiol Rev       Date:  2000-07       Impact factor: 26.132

7.  Naturally occurring core immune-escape and carboxy-terminal mutations\truncations in patients with e antigen negative chronic hepatitis B.

Authors:  Ranjit Chauhan; Shiv K Sarin; Manoj Kumar; Jayashree Bhattacharjee
Journal:  Hepatol Int       Date:  2011-12-02       Impact factor: 6.047

Review 8.  New perspective on the natural course of chronic HBV infection.

Authors:  Yong-Yuan Zhang; Ke-Qin Hu; Zhongping Duan
Journal:  Front Med       Date:  2014-05-29       Impact factor: 4.592

Review 9.  HBeAg negative variants and their role in the natural history of chronic hepatitis B virus infection.

Authors:  Alexandra Alexopoulou; Peter Karayiannis
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

10.  Genotyping and molecular characterization of hepatitis B virus from human immunodeficiency virus-infected individuals in southern Africa.

Authors:  Euphodia Makondo; Trevor G Bell; Anna Kramvis
Journal:  PLoS One       Date:  2012-09-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.